IDEXX Laboratories/$IDXX
1D1W1MYTD1Y5YMAX
Capital at risk
About IDEXX Laboratories
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
- Ticker
- $IDXX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 11,000
- Headquarters
- Westbrook, United States
- Website
- www.idexx.com
IDXX Metrics
BasicAdvanced
$41B
36.58
$14.22
1.54
-
Price and volume
Market cap
$41B
Beta
1.54
52-week high
$769.98
52-week low
$518.55
Average daily volume
585K
Financial strength
Current ratio
1.172
Quick ratio
0.64
Long term debt to equity
24.828
Total debt to equity
60.082
Interest coverage (TTM)
25.69%
Profitability
EBITDA (TTM)
1,621.685
Gross margin (TTM)
62.45%
Net profit margin (TTM)
25.03%
Operating margin (TTM)
32.23%
Effective tax rate (TTM)
19.99%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
26.92%
Return on equity (TTM)
74.21%
Valuation
Price to earnings (TTM)
36.576
Price to revenue (TTM)
9.099
Price to book
25.44
Price to tangible book (TTM)
25.44
Price to free cash flow (TTM)
33.491
Free cash flow yield (TTM)
2.99%
Free cash flow per share (TTM)
15.533
Growth
Revenue change (TTM)
12.77%
Earnings per share change (TTM)
18.41%
3-year revenue growth (CAGR)
9.02%
10-year revenue growth (CAGR)
10.42%
3-year earnings per share growth (CAGR)
14.67%
10-year earnings per share growth (CAGR)
20.49%
What the Analysts think about IDXX
Analyst ratings (Buy, Hold, Sell) for IDEXX Laboratories stock.
Analyst projections of the future price of IDEXX Laboratories stock.
Bulls say / Bears say
IDXX raised full-year 2026 revenue guidance to $4.632 billion–$4.72 billion and EPS guidance to $14.29–$14.80, modestly above consensus, reflecting management’s confidence in sustained demand for pet diagnostics. (Reuters via TradingView) (tradingview.com)
The placement of over 1,900 IDEXX inVue Dx analyzers in Q4 2025 drove a 12% year-over-year expansion of its premium instrument installed base, underpinning recurring consumable and service revenues. (Reuters via TradingView) (tradingview.com)
Q2 2026 revenues rose 10% reported (9% organic) to $1.217 billion and EPS grew 15% on a comparable basis to $4.27, with operating margin expanding 110 bps, driven by strong performance across Companion Animal, Water, and LPD segments. (Nasdaq via Business Wire) (nasdaq.com)
U.S. same-store clinical visits, particularly wellness visits, declined 3.6% in Q4 2025 and are forecast to fall about 2% in 2026, potentially limiting test volumes and revenue. (Reuters via MarketScreener) (marketscreener.com)
A $15 million foreign exchange headwind in 2026, representing approximately 0.6% of revenue growth and a $0.05 per share EPS drag, could compress margins amid currency volatility. (Yahoo Finance via company call) (finance.yahoo.com)
Instrument revenues are expected to decline in 2026 as the company laps the exceptional prior-year inVue Dx rollout and faces regional mix shifts, introducing cyclicality to top-line growth. (Motley Fool) (fool.com)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
IDXX Financial Performance
Revenues and expenses
IDXX Earnings Performance
Company profitability
Upcoming events
No upcoming events
IDXX News
AllArticlesVideos
Funds containing IDXX
AllEURUSDGBP
Fund name | Fund size | $IDXX weighting |
|---|---|---|
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.57% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.74% |
iShares Edge S&P 500 Minimum Volatility$SPMV | $1.9B | 0.38% |
iShares Edge S&P 500 Minimum Volatility€IBCK | €1.6B | 0.38% |
iShares Edge S&P 500 Minimum Volatility£MVUS | £1.4B | 0.38% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.